Olby Natasha J, Lim Ji-Hey, Wagner Nikki, Zidan Natalia, Early Peter J, Mariani Christopher L, Muñana Karen R, Laber Eric
Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina.
Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina.
J Vet Intern Med. 2019 Mar;33(2):726-734. doi: 10.1111/jvim.15439. Epub 2019 Feb 13.
A noninvasive biomarker is needed to predict recovery from severe spinal cord injury (SCI) because of thoracolumbar intervertebral disc extrusion (TL-IVDE). Proteins released from neural and glial cells can be detected in the blood and show promise as prognostic tools, but their concentration is influenced by time after injury.
HYPOTHESIS/OBJECTIVES: Serum concentrations of glial fibrillary acidic protein (GFAP), phosphorylated neurofilament heavy chain (pNFH), and S100β will follow different time courses; measurement of combinations of these proteins will predict outcome.
Thirty-one dogs with TL-IVDE causing paralysis with no pain perception.
Prospective study. Serum samples were taken at presentation and intervals over 56 days and banked at -80°C. Glial fibrillary acidic protein, pNFH, and S100β concentrations were measured using ELISA tests and plotted against time from onset of nonambulatory status. Outcome was established at 6 months. The association between biomarker concentration and outcome was examined using logistic regression, receiver operator characteristics curve analysis, and model development.
Thirty-one dogs participated, 3/31 (10%) developed progressive myelomalacia and 19/31 (62%) recovered ambulation. Glial fibrillary acidic protein and S100β concentrations rose for the first 1 to 3 days, and were undetectable by 14 and 28 days, respectively. Phosphorylated neurofilament heavy chain concentrations peaked at 14 days and were detectable at 56 days. Glial fibrillary acidic protein concentrations in the first 72 hours after onset of nonambulatory status predicted recovery with an accuracy of 76.7%-89% depending on sample timing.
Serum GFAP concentrations can be used to predict outcome in clinically complete SCI. A rapid inexpensive bedside test is needed.
由于胸腰椎椎间盘突出症(TL-IVDE)导致严重脊髓损伤(SCI),需要一种非侵入性生物标志物来预测恢复情况。从神经和胶质细胞释放的蛋白质可在血液中检测到,有望作为预后工具,但其浓度受损伤后时间的影响。
假设/目标:胶质纤维酸性蛋白(GFAP)、磷酸化神经丝重链(pNFH)和S100β的血清浓度将遵循不同的时间进程;测量这些蛋白质的组合将预测结果。
31只因TL-IVDE导致瘫痪且无疼痛感知的犬。
前瞻性研究。在就诊时及之后56天内每隔一段时间采集血清样本,并保存在-80°C。使用酶联免疫吸附测定(ELISA)测试测量GFAP、pNFH和S100β的浓度,并根据非行走状态开始后的时间进行绘制。在6个月时确定结果。使用逻辑回归、受试者操作特征曲线分析和模型开发来检查生物标志物浓度与结果之间的关联。
31只犬参与研究,3/31(10%)发生进行性脊髓软化,19/31(62%)恢复行走。GFAP和S100β浓度在最初1至3天上升,分别在14天和28天时检测不到。磷酸化神经丝重链浓度在14天达到峰值,在56天时仍可检测到。非行走状态开始后最初72小时内的GFAP浓度根据样本采集时间预测恢复的准确率为76.7%-89%。
血清GFAP浓度可用于预测临床完全性SCI的结果。需要一种快速、廉价的床边检测方法。